Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 30 of 34.
Aug 2010
Jul 2010
27 Jul · Board meeting
To consider inter-alia, the un-audited Financial Results of the Company for the quarter ended June 30, 2010.19 Jul · Business
The Compensation Committee of the Board on July 19, 2010 has made allotment of 27,007 Equity Shares of Rs.5/- each at premium of Rs.357.60 per Share under ESOP-2004 Scheme of the Company. Consequent to the allotment the paid up share capital of the Company has increased from 56453157 Equity Shares of Rs.5/- each 56480164 Equity Shares of Rs.5/-each.
Jun 2010
8 Jun · Business
May 2010
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2010 considered and approved the following: The final dividend at 40% (Rs. 2.00 per share of Rs. 5/- each) on the equity share capital of the Company for the year 2009-2010 has been recommended, subject to approval of members. The Company in the month of February, 2010 has paid an interim dividend of 60% (Rs. 3.00 per share of Rs. 5/- each) on the equity capital of the Company for the year 2009-2010.29 May · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 357543 lacs for year ending on 31-MAR-2010 against Rs. 307729 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 56340 lacs for the year ending on 31-MAR-2010 against Rs. 10026 lacs for the year ending on 31-MAR-2009.29 May · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 325227 lacs for year ending on 31-MAR-2010 against Rs. 279484 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 52576 lacs for the year ending on 31-MAR-2010 against Rs. 12854 lacs for the year ending on 31-MAR-2009.18 May · Business
5 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2010 and recommendation of final dividend, if any, for the financial year ended March 31, 2010. In view of this, the Company will not be publishing the un-audited quarterly financial results of last quarter ending March 31, 2010.
Apr 2010
29 Apr · Business
Pursuant to the approval of the Hon'ble High Court of Andhra Pardesh to the Scheme of Amalgamation of Trident Life Sciences Limited, wholly owned subsidiary with Aurobindo Pharma Limited, the Company is pleased to inform that the Scheme of Amalgamation is made effective on April 29, 2010. Further, no shares would be issued by the Company in consideration for the merger as Trident is a wholly owned subsidiary of the Company.20 Apr · Allotment of shares
Allotment of shares on Conversion of FCCBs. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Apr · Business
Press release dated April 16, 2010, titled " Aurobindo Pharma receives approvals for Cefprozil Tablets and PFOS from Health Canada" A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Apr · Business
Press release dated April 13, 2010, titled " Aurobindo Pharma receives final approval for Ondansetron Orally Disintegrating Tablets" A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Apr · Business
Press release dated April 08, 2010, titled " Aurobindo Pharma receives final approval for Venlafaxine Hydrochloride Tablets." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
22 Mar · Business
Press release dated March 20, 2010, titled "Aurobindo Pharma receives approval for Topiramate Tablets from Health Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Allotment of shares
Allotment of shares on Conversion of FCCBs. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Press release dated March 04, 2010, titled "Global Pharmaceutical Leader Aurobindo Presents AuroSource, its new division for Custom Research and Manufacturing (CRAMS)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Mar · Business
Press release dated March 03, 2010, titled "Aurobindo Pharma receives approval for Cefuroxime Axetil Tablets from Health Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended December 31,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
26 Feb · Business
Press release dated February 25, 2010, titled "Aurobindo Pharma receives tentative approval for its New Drug Application (NDA) Nevirapine Tablets for Oral Suspension 50mg". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Feb · Allotment of shares
Allotment of shares on Conversion of FCCBs. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Feb · Business
Aurobindo Pharma Ltd had informed the Exchange regarding the Scheme of Amalgamation of Trident Life Sciences Limited with Aurobindo Pharma Limited and their respective Shareholders. The Company has now informed the Exchange that "As directed by the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad by its Order dated 19th February, 2010, the Company, on February 24, 2010, has published the notice in News Papers of the date of hearing of the petition on 19th March, 2010 for the sanction of the Scheme of Amalgamation of Trident Life Sciences Limited with Aurobindo Pharma Limited and their respective Shareholders".4 Feb · Business
Press release dated February 04, 2010, titled "Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Solution (OTC)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Feb · Allotment of shares
Allotment of shares on Conversion of FCCBs. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
30 Jan · Dividend
Board of Directors of the Company at their meeting held on January 30, 2010 has approved payment of an interim dividend @ 60% i.e. Rs. 3/- (Rupees three only) per Equity Share of Rs. 5/- (Rupees five only) each to the members of the Company for the Current Financial Year 2009-2010.30 Jan · Business
Press release dated January 30,2010 titled " Aurobindo Pharma Q3 2009-10 Unaudited Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 91524 lacs for quarter ending on 31-DEC-2009 against Rs. 73511 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 17177 lacs for the quarter ending on 31-DEC-2009 against Rs. 4184 lacs for the quarter ending on 31-DEC-2008.30 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 81106 lacs for quarter ending on 31-DEC-2009 against Rs. 67678 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 14826 lacs for the quarter ending on 31-DEC-2009 against Rs. 4072 lacs for the quarter ending on 31-DEC-2008.22 Jan · Outcome of Court Convened Meeting
Shareholders of the Company at their meeting held on January 20, 2010 as per the directions of the Hon'ble High Court of Andhra Pradesh at Hyderabad, have approved the Scheme of Amalgamation between Trident Life Sciences Limited (a wholly owned subsidiary of Aurobindo Pharma Limited) and Aurobindo Pharma Limited and their respective Shareholders.18 Jan · Board meeting
Meeting on 30 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009/Unaudited Financial Results/Dividend/Record date”7 Jan · Allotment of shares
Allotment of shares on Conversion of FCCBs. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Jan · Notice of Meeting
By an order made on December 09, 2009, in Aurobindo Pharma Limited's Application, the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has directed that a meeting of the Equity Shareholders of the Applicant Company i.e. Aurobindo Pharma Limited, be convened and held on January 20, 2010, for the purpose of considering and if thought fit approving, with or without modification(s), the Scheme of Amalgamation proposed to be made between Trident Life Sciences Limited and Aurobindo Pharma Limited and their respective shareholders. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
29 Dec · Meeting
At the Annual General Meeting of the Company held on December 23, 2009, the members have approved the following:(1) Audited annual account for the year 2008-2009.(2) Final Dividend @ 30% i.e. Rs. 1.50 per share (Interim Dividend @ 60% i.e. Rs. 3.00 per share already paid ) for the year 2008-2009.(3) Re-appointment of Dr. M Sivakumaran, Mr. M Madan Mohan Reddy and Mr. M. Sitarama Murthy as Directors of the Company.(4) Re-appointment of S.R Batliboi & Associates, as Statutory Auditors of the Company.(5) Revision of remuneration of Mr. P. V. Ramprasad Reddy, Chairman, Mr. K. Nithyananda Reddy, Managing Director and Dr. M. Sivakumaran whole time Director.(6) Re-appointment of Dr. M Sivakumaran, Mr. M Madan Mohan Reddy as Wholetime Directors of the Company.(7) Appointment of Ms. K Kirthy Reddy and Mr. Vishnu M Sriram under section 314 of the Companies Act, 1956.(8) Appointment of Dr. D. Rajagopala Reddy as Director of the Company.17 Dec · Business
Press release dated December 17, 2009, titled "Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Syrup (Rx)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Dec · Business
Press release dated December 15, 2009, titled "Aurobindo Pharma receives approval for Citalopram Hydrobromide tablets from TGA, Australia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Dec · Allotment
The Compensation Committee of the Board on 15th December, 2009 has approved allotment of 1,50,030 Equity Shares of Rs.5/- each at a premium of Rs.357.60 per share under ESOP-2004 Scheme of the Company. Consequent to the allotment the paid up share capital of the Company has increased from 53848389 Equity Shares of Rs.5/- each to 53998419 Equity Shares of Rs.5/- each.2 Dec · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended September 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
23 Nov · Business
Press release dated November 23, 2009, titled "Aurobindo Pharma celebrates the inauguration of its formulations manufacturing facility (Unit VII) in Special Economic Zone, Hyderabad India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Nov · Results
Consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 307729 lacs for year ending on 31-MAR-2009 against Rs. 243590 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 10026 lacs for the year ending on 31-MAR-2009 against Rs. 23848 lacs for the year ending on 31-MAR-2008.12 Nov · Results
Standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 279484 lacs for year ending on 31-MAR-2009 against Rs. 223473 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 12854 lacs for the year ending on 31-MAR-2009 against Rs. 29078 lacs for the year ending on 31-MAR-2008.12 Nov · Meeting
Board of Directors of the Company at its meeting held on November 12, 2009 has inter-alia considered and approved the following: 1) The draft Scheme of Amalgamation for the merger of Trident Life Sciences Limited being wholly owned subsidiary of the Company, with itself. Upon the Scheme becoming effective, all the assets and liabilities of Trident shall be transferred to Aurobindo. Aurobindo shall not issue any shares or other consideration as Trident is 100% subsidiary of Aurobindo. The Scheme is subject to requisite consent, approval of the requisite majority of the shareholders of the companies, the Hon'ble High Court of Judicature at Hyderabad, Stock Exchanges, the permission or approval of any other statutory or regulatory authorities, which by law may be necessary for the implementation of the Scheme. 2) To convene the Annual General Meeting of the Company on December 23, 2009. 3) The Register of Members and Share Transfer Books of the Company will be closed from December 18, 2009 to December 23, 2009 (both days inclusive) for the purpose of Annual General Meeting and for payment of dividend for the year 2008-09.